HERPES VACCINE IN DEVELOPMENT FAILS DURING CLINICAL TRIALS

• HERPES VACCINE IN DEVELOPMENT FAILS DURING CLINICAL TRIALS

  Vical Inc. said its genital herpes vaccine didn’t meet the primary endpoint in a Phase 1/Phase 2 clinical trial.
  Those who suffer from a genital herpes infection may be disappointed to learn that a potential herpes vaccine under development from Vical Inc. has failed to meet expectations during initial clinical trials. As reported, the vaccine “didn’t meet the primary endpoint of reducing viral shedding.” Vijay Samant, president and CEO of Vical said “We just received the top-line study data and we are disappointed that the vaccines did not meet the primary endpoint. The trial is ongoing and all patients are being followed for safety for 12 months and efficacy for nine months after their final vaccine dose.” Due to the failure of the vaccine candidate, Vical's company shares fell by 47%. As reported, “the biopharmaceutical company’s shares were down 47% to 75 cents in after-hours trading.”
  The Center for the Biology of Chronic Disease (CBCD) is also disappointed in the results of the vaccine's clinical trials, since removing herpes from a long list of chronic diseases would be an important step forward for medicine.
  Developing an effective, therapeutic vaccine against the herpes virus (HSV-1 and HSV-2) and gaining FDA approval takes time. Until any new anti-herpes vaccine is FDA approved, the CBCD recommends that infected individuals take Gene-Eden-VIR or Novirin, which are natural herpes remedies with a formula backed by clinical studies that followed FDA guidelines.Gene-Eden-VIR and Novirin, which were designed to help the immune system target the latent HSV in those already infected.
  (URL.: http://cosmetics.einnews.com/pr_news/276048727/herpes-vaccine-in-development-fails-during-clinical-trials-the-cbcd-reviews-a-report)